General Archive
-
News releasesLifeArc announces seed fund investment in start-up GyreOx
The funding will support a two-year programme to develop and automate GyreOx’s proprietary drug discovery platform, MACRO.
-
News releasesLifeArc boosts investment in Cambridge University spin-out PolyProx Therapeutics to advance new class of cancer medicines
The investment will help advance studies to validate polyproxin® molecules as potential drug candidates across a range of cancers.
-
News releasesLifeArc and Scottish Government Chief Scientist Office launch new funding scheme to boost translational research in Scotland
Funding aims to progress strong discovery science to a point where additional substantive funding could be secured.
-
News releasesLifeArc and Action Medical Research launch funding call for research into rare diseases in children
£1m for translational research projects focussed on children’s rare diseases
-
News releasesLifeArc appoints new Chief Investment Officer (CIO)
Graham Duce appointed to the newly created role of CIO to ensure that we have a sustainable approach to income…
-
News releasesCelebrating the successes of UK translation – our 2019 annual reception
Melanie Lee, LifeArc CEO acknowledges the success of the life sciences and translational research sectors in the UK
-
News releasesPatients with ultra-rare bone marrow disease set to benefit from £1.15m grant from LifeArc and The Aplastic Anaemia Trust
A research grant to investigate the potential of a novel type of “personalised cellular therapy” to reverse the ultra-rare condition,…
-
News releasesLifeArc Seed Fund makes £1.5million investment in Caldan Therapeutics to develop novel treatments for metabolic diseases
Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories
-
News releasesKymab and LifeArc enter strategic partnership to discover new medicines using Kymab’s IntelliSelect® technologies
The agreement will enable LifeArc to enhance our antibody drug discovery capabilities
-
News releasesLifeArc invests £1.5 million in Ducentis BioTherapeutics
LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease
-
News releasesLifeArc monetises Keytruda® royalty interests to fund further research and investment
LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical…
-
News releasesMedicines Discovery Catapult and LifeArc launch strategic R&D partnership in biomarker discovery and proteomics technology
Three-year partnership to fund clinical application of biomarker strategies to help progress novel drug candidates to clinical evaluation stage